Suppr超能文献

开发 STEP-SE:用于管理精神分裂症谱系障碍护理中共享决策副作用的新型患者报告结局工具的定性可用性研究。

Developing STEP-SE: A Qualitative Usability Study of a Novel Patient-Reported Outcomes Tool for Managing Side Effects in Shared Decision-Making for Schizophrenia Spectrum Disorder Care.

机构信息

Department of Clinical and Experimental Medicine, Institute of Psychiatry, University of Catania, Catania, Italy.

Department of Psychiatry and Psychotherapy, Technical University of Munich, TUM School of Medicine and Health, Munich, Germany.

出版信息

Health Expect. 2024 Dec;27(6):e70019. doi: 10.1111/hex.70019.

Abstract

BACKGROUND

Schizophrenia treatment with antipsychotics often results in side effects that impact adherence and quality of life. Managing these effects remains challenging, as it requires balancing efficacy and tolerability. The Schizophrenia Technological Evaluation of Patient Side Effects (STEP-SE) app aims to aid side effects monitoring and management through shared decision-making (SDM).

AIM

This study aimed to evaluate the usability of the STEP-SE app for patients and clinicians in managing antipsychotic side effects.

METHODS

Sixteen stable outpatients and 14 psychiatrists participated in semi-structured interviews after using the STEP-SE app. Questions explored ease of use, information clarity, user needs fulfilment, patient-clinician collaboration, treatment adherence improvement, patient empowerment and clinical utility. Data were analysed thematically.

RESULTS

Overall satisfaction with STEP-SE was high. Both groups found that the tool improved patient involvement, provided reliable information to enhance therapeutic alliance, posed low risks of misunderstanding and had an intuitive interface. Patients felt more motivated and empowered. Clinicians appreciated guideline consistency. Preferences differed regarding data visualization formats.

DISCUSSION

STEP-SE shows potential for aiding SDM on antipsychotic side effects. Patients gained motivation, and clinicians felt reassured. Refinements around mobile access, graphics and features could augment utility. Generalizability is limited given the stable patient sample.

CONCLUSION

Preliminary findings suggest that STEP-SE effectively engages patients, empowers them and supports clinicians in collaborative side effect management. Further testing with diverse user groups is warranted.

PATIENT OR PUBLIC CONTRIBUTION

The current study was designed to gather patient and public feedback for the development of our decision aid tool, STEP-SE. Participants interacted with the tool's prototype in interactive sessions, providing insights and identifying technical issues. Their feedback was crucial for enhancing the tool, with each suggestion and bug report carefully considered for future iterations. The participants' contributions were key in optimizing STEP-SE's features and ensuring its relevance and reliability. We thank all who shared their time and perspectives, significantly shaping the tool's user-centred design.

摘要

背景

精神分裂症的抗精神病药物治疗常常导致影响依从性和生活质量的副作用。管理这些影响仍然具有挑战性,因为它需要平衡疗效和耐受性。精神分裂症患者副作用的技术评估(STEP-SE)应用程序旨在通过共享决策(SDM)来帮助监测和管理副作用。

目的

本研究旨在评估 STEP-SE 应用程序在管理抗精神病药物副作用方面对患者和临床医生的可用性。

方法

16 名稳定的门诊患者和 14 名精神科医生在使用 STEP-SE 应用程序后参加了半结构化访谈。问题探讨了易用性、信息清晰度、用户需求满足、医患合作、治疗依从性改善、患者赋权和临床实用性。数据进行了主题分析。

结果

对 STEP-SE 的总体满意度很高。两组都认为该工具提高了患者的参与度,提供了可靠的信息来增强治疗联盟,误解的风险较低,界面直观。患者感到更有动力和赋权。临床医生赞赏指南的一致性。对数据可视化格式的偏好不同。

讨论

STEP-SE 显示出在抗精神病药物副作用的 SDM 方面有潜力。患者获得了动力,临床医生感到放心。改进移动访问、图形和功能可以提高实用性。鉴于稳定的患者样本,推广性有限。

结论

初步结果表明,STEP-SE 有效地吸引患者,赋予他们权力,并支持临床医生进行协作的副作用管理。需要进一步测试不同的用户群体。

患者或公众贡献

本研究旨在收集患者和公众的反馈意见,以开发我们的决策辅助工具 STEP-SE。参与者在互动会议中与工具的原型进行交互,提供见解并确定技术问题。他们的反馈对增强工具至关重要,每个建议和错误报告都被仔细考虑用于未来的迭代。参与者的贡献是优化 STEP-SE 的功能并确保其相关性和可靠性的关键。我们感谢所有分享他们的时间和观点的人,他们极大地塑造了工具的以用户为中心的设计。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验